Annovis Bio Inc. (NYSE: ANVS) announced it has regained compliance with New York Stock Exchange (NYSE) continued listing standards, a critical milestone that allows its common stock to continue trading on the NYSE under the ticker symbol ANVS. The company implemented corrective measures to restore its market capitalization and stockholders' equity above required thresholds, though specific measures were not disclosed.
The NYSE requires listed companies to maintain certain financial standards, including minimum market capitalization and stockholders' equity. After falling below these thresholds, Annovis took steps to address the deficiencies. Regaining compliance removes a significant overhang for the company, enabling it to focus on its clinical development programs without the distraction of potential delisting. Continued listing on the NYSE provides liquidity and visibility to investors and may boost investor confidence, as it assures the company's financial health and adherence to regulatory standards.
Annovis Bio is a Phase 3 clinical-stage biotechnology company developing treatments for Alzheimer's disease and Parkinson's disease. The company is focused on developing buntanetap (formerly posiphen), an investigational once-daily oral therapy that targets the underlying causes of neurodegeneration. The drug candidate inhibits the translation of multiple neurotoxic proteins, including amyloid beta, tau, alpha-synuclein, and TDP-43, through a specific RNA-targeting mechanism of action. By addressing these proteins, Annovis aims to halt disease progression and improve cognitive and motor functions in patients with Alzheimer's disease and Parkinson's disease.
The company is currently conducting Phase 3 clinical trials for buntanetap in both Alzheimer's and Parkinson's diseases. Positive results from these trials could position buntanetap as a potential disease-modifying therapy for millions of patients worldwide. Alzheimer's disease affects an estimated 6.7 million Americans, while Parkinson's disease impacts nearly one million people in the United States, according to the Alzheimer's Association and the Parkinson's Foundation.
For more information about Annovis Bio and its pipeline, visit the company's website at https://www.annovisbio.com. The latest news and updates relating to ANVS are available in the company's newsroom at https://ibn.fm/ANVS.
